Business Wire12d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...
Pharmabiz14h
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
FierceBiotech4d
ADC Therapeutics axes lead solid tumor drug after phase 1 setback, pivots to preclinical programs
The biotech is prioritizing its exatecan-based platform for solid tumors. Exatecan, a potent inhibitor of topoisomerase I, is at the center of ADC’s next wave of candidates. The biotech has ...
pharmaphorum2y
FDA gives Daiichi Sankyo's HER3 drug a breakthrough tag
Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...
Medscape8mon
Trastuzumab Deruxtecan: Effects in Multiple Cancer Types
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
pharmaphorum3y
AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecan
AstraZeneca and Daiichi Sankyo have revealed new data from datopotamab deruxtecan in triple negative breast cancer (TNBC) – and although it’s from a small patient group results look impressive.
The Globe and Mail6d
HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with ...
La Razón Digital5d
Ya está disponible trastuzumab deruxtecán contra el cáncer de mama metastásico HER2-low en todas las autonomías
La investigación continúa. De hecho, como ha demostrado el estudio "Destiny Breast 06", presentado este año, trastuzumab-deruxtecan mejora resultados en cáncer de mama metastásico en ...
London South East29d
Avacta Group Share Chat (AVCT)
Re: "Enhertu (Trastuzumab Deruxtecan), Exatecan (Deruxtecan being a derivative), Trodelvy (Sacituzumab Govitecan) – plus several other products delivering SN-38, or even Keytruda (Pembolizumab)?" ...
Morningstar12d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Datopotamab deruxtecan is a specifically engineered ... attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.
ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...
London South East21d
Avacta Group Share Chat (AVCT)
The market leading antibody-drug conjugate, Enhertu (co-owned by Daiichi Sankyo and AstraZeneca), uses a derivative of exatecan (deruxtecan) as its warhead. Note that the consensus forecast is for ...